Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA

World's First FDA IDE Coronary Patient Treated With a DEB


NYON, Switzerland, July 11, 2020 /PRNewswire/ --  MedAlliance has announced enrollment of the first patient in its study of SELUTION SLRtm 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Program'. The SELUTION SLR (Sustained Limus Release) is a novel sirolimus eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).

MedAlliance_Logo

The objectives of this prospective, randomized, single-blind multicenter study are to demonstrate the safety and efficacy of SELUTION SLR in treatment of ISR with either drug-eluting or bare metal stents (BMS). The study will support submission for FDA approval.

"This first patient was treated with the investigational device after suffering a DES ISR. We are delighted to be able to offer our patients this promising new technology," commented Professor Pascal Vranckx, Hartcentrum Hasselt, Belgium. "We are excited to participate in a study that validates this novel technology for ISR treatment. SELUTION SLR may provide an additional treatment option for these patients. We very much look forward to the results of this study."

Up to 418 subjects will be recruited into the study at approximately 60 sites across both the US and Europe. Subjects need to have a BMS or DES ISR involving a native coronary artery with a reference vessel diameter (RVD) of 2.00 ? 4.50 mm to qualify for inclusion. Subjects will be randomized to receive either SELUTION SLR or Standard of Care (SOC) ? a control group with a current DES or a non-drug eluting balloon angioplasty.

The primary endpoint for effectiveness of the study is Target Lesion Failure (TLF): defined as all cardiac death; target vessel myocardial infarction; or clinically driven Target Lesion Revascularization (TLR) at 12 months.

Subjects will be followed up at one month, six months, 12 months and then annually through five years.

"This is a particularly important study for MedAlliance," explained Chairman and CEO Jeffrey B. Jump. "No coronary drug-eluting balloon has yet been approved in the US, where ISR currently represents 11% of all stent implantations. We are excited to introduce this breakthrough technology to help patients around the world."

The Principal Investigator of this study is Donald Cutlip, Professor of Medicine at Harvard Medical School and Chief Medical Officer at the Baim Institute for Clinical Research. Professor Cutlip helped design the study in consultation with the Institute.

SELUTION SLR's technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and Sustained Limus Release (SLR) of the drug. Extended release of sirolimus from stents has been demonstrated highly efficacious in both coronary and peripheral vasculatures. MedAlliance's proprietary CATtm (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.

SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020. It is now is available in Europe and all other countries where the CE Mark is recognized. The global market for DEB is estimated to be $2 Billion.

About MedAlliance

MedAlliance is a privately-owned medical technology company. It is headquartered in Switzerland, with facilities in Irvine, California; Glasgow, UK; and Singapore. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: http://medalliance.com/

Media Contact: 
Richard Kenyon
rkenyon@medalliance.com
+44-7831-569940

Logo: https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg

 


These press releases may also interest you

at 11:10
According to a new market research report titled "Probiotics Market by Product Type (Functional Food & Beverages, Medical & Dietary Supplements, Animal Feed), Strain (Bacteria, Yeast), Form (Dry, Liquid), Sales Channel (Offline, Online), and...

at 11:01
Vyne, a recognized market leader in health information exchange and electronic healthcare communication management, announced today a rebrand of its dental business. The Vyne Dental® brand reflects the company's evolution into a complete revenue...

at 11:00
The latest data of the evolution of COVID-19 in Québec reveal 123 new cases, bringing the total number of people infected to 59,722. During the same period, 1 new death was recorded, to which is added 1 death that occurred before July 26, for a total...

at 11:00
As the COVID-19 pandemic continues nationally and worldwide, TIDI Products is committed to supporting those on the front lines, and has developed a new PPE option to help keep healthcare providers safe....

at 11:00
According to Stratistics MRC, the Global Blood Glucose Monitoring Systems Market is accounted for $9.45 billion in 2019 and is expected to reach $15.41 billion by 2027 growing at a CAGR of 6.3% during the forecast period. Some of the key players...

at 11:00
The global syringe and needle market is expected to grow at a CAGR of over 10% during the period 2019?2025. Key Highlights Offered in the Report:   Safety needles are the major leading segment and are growing at a faster growth rate, thereby...



News published on 11 july 2020 at 03:00 and distributed by: